Search

Your search keyword '"LifeCore Biomedical Inc."' showing total 717 results
Start Over Descriptor "LifeCore Biomedical Inc."
717 results on '"LifeCore Biomedical Inc."'

1. Q1 2025 Lifecore Biomedical Inc Earnings Call - Final

Subjects
LifeCore Biomedical Inc., Biological products industry, Business
Abstract

Presentation OPERATOR: Good morning, and thank you for joining Lifecore's fiscal 2025 first quarter earnings call. (Operator Instructions) Now, I'd like to turn the call over to Stephanie Diaz, Manager [...]

Published
2024

2. Lifecore Biomedical to Present at Stephens Annual Investment Conference

Subjects
LifeCore Biomedical Inc., Biological products industry, Conferences and conventions, General interest, News, opinion and commentary
Abstract

CHASKA: Lifecore Biomedical, Inc. has issued the following news release: Lifecore Biomedical, Inc. (NASDAQ: LFCR) ('Lifecore'), a fully integrated contract development and manufacturing organization ('CDMO'), today announced that Paul Josephs, [...]

Published
2024

4. Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations

Subjects
LifeCore Biomedical Inc.
Abstract

ENPNewswire-November 5, 2024--Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 04112024 - Lifecore Biomedical, Inc. (NASDAQ: LFCR) ('Lifecore'), a fully integrated contract development [...]

Published
2024

5. Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Subjects
LifeCore Biomedical Inc., Biological products industry
Abstract

ENPNewswire-October 7, 2024--Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 04102024 - CHASKA - Lifecore Biomedical, Inc. ('Lifecore'), a fully integrated [...]

Published
2024

6. Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Subjects
LifeCore Biomedical Inc., Biological products industry, Private placements (Securities), Stocks, Banking, finance and accounting industries, Business
Abstract

CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ('Lifecore'), a fully integrated contract development and manufacturing organization ('CDMO'), today announced the closing of a $24.3 million private [...]

Published
2024

8. 8-K: LIFECORE BIOMEDICAL, INC. \DE

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Latham & Watkins L.L.P., Biological products industry, Law firms, Business, general
Abstract

(EDGAR Online via COMTEX) -- FALSE000100528600010052862024-10-032024-10-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

Published
2024

9. LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Securities fraud, Law firms, Class actions (Civil procedure), Financial statements, Business, Business, international
Abstract

LOS ANGELES -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ('Lifecore' or 'the Company') (NASDAQ: LFCR) [...]

Published
2024

10. The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)

Subjects
LifeCore Biomedical Inc., Biological products industry, Class actions (Civil procedure), Hazardous waste management industry, Financial statements, Stockholders' derivative actions, Business, Business, international
Abstract

LOS ANGELES -- The Law Offices of Frank R. Cruz reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed [...]

Published
2024

14. Lifecore Biomedical Regains Compliance with Nasdaq Listing Requirements

Subjects
LifeCore Biomedical Inc., Biological products industry, Regulatory compliance, Stock-exchange -- Listings, General interest, News, opinion and commentary
Abstract

CHASKA: Lifecore Biomedical, Inc. announced that it has received written notice from the Nasdaq Listing Qualifications Department stating that the Company has regained compliance with the filing requirement in Nasdaq [...]

Published
2024

15. Faruqi & Faruqi Reminds Lifecore Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 27, 2024 - LFCR

Subjects
LifeCore Biomedical Inc., Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, General interest, News, opinion and commentary
Abstract

NEW YORK: Faruqi & Faruqi LLP has issued the following news release: Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lifecore Biomedical, Inc. [...]

Published
2024

16. Glancy Prongay & Murray LLP Reminds Investors of Class Action Lawsuit Against Lifecore Biomedical, Inc

Subjects
LifeCore Biomedical Inc., Biological products industry, Class actions (Civil procedure), Hazardous waste management industry, Financial statements, Stockholders' derivative actions, General interest, News, opinion and commentary
Abstract

LOS ANGELES: Glancy Prongay & Murray LLP reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of [...]

Published
2024

17. FORM 8-K: LIFECORE BIOMEDICAL, INC. \DE\ Files Current Report (Sep 12, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., The NASDAQ Stock Market L.L.C., Securities law, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: LIFECORE BIOMEDICAL, INC. \DE\, has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Sep 12, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. [...]

Published
2024

18. Robbins LLP Reminds Investors of Class Action on Behalf of Lifecore Biomedical, Inc

Subjects
LifeCore Biomedical Inc., Biological products industry, Financial disclosure, Biological products, Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. securities between [...]

Published
2024

19. Bernstein Liebhard LLP Reminds Lifecore Biomedical, Inc. Investors of Upcoming Deadline

Subjects
LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), General interest, News, opinion and commentary
Abstract

NEW YORK: Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that [...]

Published
2024

20. Glancy Prongay & Murray LLP Reminded Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)

Subjects
LifeCore Biomedical Inc., Biological products industry, Class actions (Civil procedure), Stockholders' derivative actions, General interest, News, opinion and commentary
Abstract

LOS ANGELES: Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf [...]

Published
2024

21. LIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Lifecore Biomedical, Inc. Investors of Upcoming Deadline

Subjects
LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), Banking, finance and accounting industries, Business
Abstract

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR)? Did you purchase your shares between [...]

Published
2024

22. ROSEN, LEADING INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LFCR

Subjects
The Rosen Law Firm P.A., LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), Banking, finance and accounting industries, Business
Abstract

NEW YORK, Sept. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October [...]

Published
2024

23. Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)

Subjects
LifeCore Biomedical Inc., Biological products industry, Class actions (Civil procedure), Hazardous waste management industry, Financial statements, Stockholders' derivative actions, Banking, finance and accounting industries, Business
Abstract

LOS ANGELES, Sept. 05, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=RCM1bpBZ0teBop2m1uRXbGcSvfCbsydUAlbF1oE8TvltLjaNiEjdqLMDh0QHBQVhs-hpL6Q1RqJkExmmEoKnV8muW-tJbyCrV0gdg9EMhTA= ('GPM') reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed [...]

Published
2024

24. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lifecore, Spire Global, Oddity Tech, and Arbor Realty and Encourages Investors to Contact the Firm

Subjects
LifeCore Biomedical Inc., Arbor Realty Trust Inc., Biological products industry, Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, Real estate investment trusts, Real property, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf [...]

Published
2024

25. Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity

Subjects
LifeCore Biomedical Inc., Biological products industry, Law firms, Securities law, Class actions (Civil procedure), General interest, News, opinion and commentary
Abstract

NEW YORK: Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. and certain of [...]

Published
2024

29. Lifecore Biomedical, Inc. Files SEC Form S-1, General Form For Registration of Securities Under The Securities Act of 1933: (Oct. 10, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Securities law, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

30. Lifecore Biomedical, Inc. Files SEC Form S-8, Securities To Be Offered To Employees in Employee Benefit Plans: (Oct. 10, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Employee benefits, Employee benefits, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

31. Lifecore Biomedical, Inc. Files SEC Form POS AM, Post-effective Amendments For Registration Statement: (Oct. 10, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

32. Lifecore Biomedical, Inc. Files SEC Form EFFECT, Notice of Effectiveness: (Oct. 16, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

33. Lifecore Biomedical, Inc. Files SEC Form SC 13D/A, General Statement of Acquisition of Beneficial Ownership: (Oct. 7, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

34. Lifecore Biomedical, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Oct. 7, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

36. Lifecore Biomedical, Inc. Files SEC Form 4/A, Statement of Changes in Beneficial Ownership of Securities: (Sept. 16, 2024)

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry, Business, Pharmaceuticals and cosmetics industries, Health
Abstract

2024 SEP 30 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities [...]

Published
2024

37. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lifecore, Seritage, Oddity Tech, and Arbor Realty and Encourages Investors to Contact the Firm

Subjects
LifeCore Biomedical Inc., Arbor Realty Trust Inc., Biological products industry, Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, Real estate investment trusts, Real property, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf [...]

Published
2024

38. Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update

Subjects
United States. Securities and Exchange Commission, LifeCore Biomedical Inc., Biological products industry
Abstract

ENPNewswire-August 27, 2024--Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 26082024 - CHASKA - Lifecore Biomedical, [...]

Published
2024

39. Pending Lead Plaintiff Deadline in the LFCR Class Action: Robbins LLP Reminds Stockholders With Large Losses of Lifecore Biomedical, Inc. to Seek Counsel

Subjects
LifeCore Biomedical Inc., Biological products industry, Biological products, Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, Stockholders, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Robbins LLP has issued the following news release: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased [...]

Published
2024

40. ROSEN, LEADING INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LFCR

Subjects
The Rosen Law Firm P.A., LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), General interest, News, opinion and commentary
Abstract

NEW YORK: The Rosen Law Firm PA has issued the following news release: WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, [...]

Published
2024

41. Kirby McInerney LLP Reminds Lifecore Biomedical, Inc. (LFCR) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Subjects
LifeCore Biomedical Inc., Biological products industry, Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, Business, Business, international
Abstract

NEW YORK -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Minnesota [...]

Published
2024

42. Pending Lead Plaintiff Deadline in the LFCR Class Action: Robbins LLP Reminds Stockholders With Large Losses of Lifecore Biomedical, Inc. to Seek Counsel

Subjects
LifeCore Biomedical Inc., Biological products industry, Financial disclosure, Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, Stockholders, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=EXFOVACG0wrl5gMnFRBlcXMzzeruMIKggMZNjyAWnj5Y3p-Zb5k50QnZ9dBMcPPOJOuhEiVcAetzm6oOk3iiQS3yjog0jGdl5QsjFOWT6BQA6l0xcdTSEjrNWoQ-aJej reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired [...]

Published
2024

43. Shareholder Rights Law Firm Robbins LLP Urges LFCR Stockholders to Contact the Firm for Information About the Lifecore Biomedical, Inc. Class Action

Subjects
LifeCore Biomedical Inc., Biological products industry, Financial disclosure, Class actions (Civil procedure), Financial statements, Stockholders, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=m4GB6k6xOLQ6-w23Xv8_ifmDGybEH1zzSpfMdTKFNuW2yJwof6INsVbEl8s5prsHKdZICvELlphhljRvWVBZ1REjLvPNgeXe0Ht6mUYy2Mbldv8ZNUrmwiCjsV78RWbj reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired [...]

Published
2024

44. ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR

Subjects
The Rosen Law Firm P.A., LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), Attorneys, Business, international, Law
Abstract

(GlobeNewswire) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, [...]

Published
2024

45. ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LFCR

Subjects
The Rosen Law Firm P.A., LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), Attorneys, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October [...]

Published
2024

46. ROSEN, A LEADING NATIONAL FIRM, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LFCR

Subjects
The Rosen Law Firm P.A., LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), Banking, finance and accounting industries, Business
Abstract

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October [...]

Published
2024

49. LFCR CLASS ACTION ALERT: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Lifecore Biomedical, Inc. Class Action

Subjects
LifeCore Biomedical Inc., Financial disclosure, Class actions (Civil procedure), Financial statements, Stockholders' derivative actions, Stockholders, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=VEhcsO5yMoYhRXWt7l2zHT3lhVuh5Tl_CHB_TgokC-G7owYvwTfuY4vyMwfG_9XP5mw96l7KIYx1FT1kx4zHvUMtwizgiwhQPC2XPRDHl6zqgqHUwnOT_jB03tkUD2VJ reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired [...]

Published
2024

50. ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LFCR

Subjects
The Rosen Law Firm P.A., LifeCore Biomedical Inc., Biological products industry, Law firms, Class actions (Civil procedure), Banking, finance and accounting industries, Business
Abstract

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results